Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8099701 | 0.85 | KMT2A (0.47) | NPC1KMT2ASMN1; SMN2LMNAHPGD | |
| Water SCHEMBL27477225 | 0.84 | KMT2A (0.46) | NPC1KMT2ASMN1; SMN2LMNAHPGD | |
| SCHEMBL13140451 | 0.81 | NPC1 (0.53) | NPC1KMT2ASMN1; SMN2LMNAHPGD | |
| SCHEMBL4715867 | 0.80 | PTPN2 (0.40) | NPC1KMT2ALMNAHPGDNPSR1 | |
| SCHEMBL12166529 | 0.78 | KMT2A (0.50) | NPC1KMT2ASMN1; SMN2LMNAHPGD | |
| SCHEMBL12713415 | 0.75 | NPC1 (0.47) | NPC1KMT2ASMN1; SMN2LMNAHPGD | |
| SCHEMBL26981928 | 0.74 | KMT2A (0.46) | NPC1KMT2ASMN1; SMN2LMNAHPGD | |
| SCHEMBL1847138 | 0.74 | KMT2A (0.48) | NPC1KMT2ASMN1; SMN2LMNAHPGD | |
| SCHEMBL3592637 | 0.74 | KMT2A (0.44) | NPC1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1847139 | 0.74 | KMT2A (0.48) | NPC1KMT2ASMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4216958-A2 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022067100-A2 | PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-31 | — | — | WO | disclosed |
| US-9657031-B2 | Ant-ligands molecules and biological applications | UNIVERSITE DE VERSAILLES-SAINT-QUENTIN-EN-YVELINES (FR) | 2017-05-23 | — | — | US | disclosed |
| US-9657031-B2 | Ant-ligands molecules and biological applications | UNIVERSITE DE VERSAILLES-SAINT-QUENTIN-EN-YVELINES (FR) | 2017-05-23 | — | — | US | disclosed |
| WO-2017045750-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017045750-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-9212143-B2 | Small molecule inhibitors of protein kinases | LEVOLTA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212143-B2 | Small molecule inhibitors of protein kinases | LEVOLTA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9034907-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-05-19 | — | — | US | disclosed |
| US-6472391-B2 | INHIBIT PHOSPHORYLATION OF PDGF RECEPTOR TO HINDER ABNORMAL CELL GROWTH AND CELL WANDERING; TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS. | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6262058-B1 | Pyrimidin-4-one derivatives as pesticide | SYNGENTA CROP PROTECTION, INC. | 2001-07-17 | — | — | US | disclosed |
| US-6207667-B1 | USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6169088-B1 | FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0888359-A1 | PYRIMIDIN-4-ONE DERIVATIVES AS PESTICIDE | Novartis AG (CH) | 1999-01-07 | — | — | EP | disclosed |
| EP-0882717-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997033890-A1 | PYRIMIDIN-4-ONE DERIVATIVES AS PESTICIDE | NOVARTIS AG (CH) | 1997-09-18 | — | — | WO | disclosed |
| US-4442289-A | ANTIASTHMA | HOFFMANN-LA ROCHE INC. (US) | 1984-04-10 | — | — | US | disclosed |
| US-4376121-A | Antiallerigically-active imidazothienopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1983-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | PDGFRB, MKI67, PDGFRA | NPC1 3532/4885KMT2A 4546/4885SMN1; SMN2 3955/4885 |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | PLK1, PLK4, BUB1B | NPC1 3211/4885KMT2A 1542/4885SMN1; SMN2 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.